How Common Is Aspergillus niger Compared With A. fumigatus?
At a Glance
Aspergillus fumigatus is generally more common overall and is the leading cause of serious lung and invasive aspergillosis. Aspergillus niger is often found in fungal ear infections, while a positive respiratory culture may reflect colonization rather than active disease.
In this answer
4 sections
When looking at Aspergillus (a genus of molds) infections overall, Aspergillus niger is generally less common than Aspergillus fumigatus, which is the most frequent cause of aspergillosis globally [1][2]. However, comparing the two is not just about which is more common overall. The frequency of A. niger depends heavily on where the infection is located and the patient’s underlying health [3].
Location Determines Which is More Common
A. niger and A. fumigatus tend to cause different types of infections:
- Fungal Ear Infections (Otomycosis): In fungal infections of the outer ear canal, A. niger (and its close relatives) is often one of the most commonly isolated Aspergillus groups [4][3]. While other fungi like Candida also frequently cause ear infections, when an Aspergillus mold is the culprit, it is very often A. niger.
- Lung Infections and Invasive Disease: In the lungs—including chronic pulmonary aspergillosis (CPA) and invasive aspergillosis (which involves tissue invasion in the lungs or dissemination to other organs)—A. fumigatus is more common [5][6]. In studies of patients with blood disorders or those in intensive care units, A. fumigatus accounts for the majority of these severe cases, with A. niger making up a smaller percentage [5][7].
- Colonization vs. Infection: Finding A. niger in a respiratory culture does not always mean it is causing active disease. In some people, it represents colonization—meaning the fungus is present in the airways but isn’t causing harm [8][9]. However, for people with weakened immune systems, compatible symptoms, or specific changes on chest imaging, that same lab result can be a sign of a serious infection. Your doctor will combine lab results with imaging and your symptoms to determine if you need treatment.
Why Exact Numbers Are Hard to Pin Down
Getting exact percentages for how common A. niger is can be challenging because of how fungi are identified in routine hospital laboratories:
- The Aspergillus niger Group (Section Nigri): Fungi are classified into taxonomic groups. A. niger belongs to a group of dark-colored molds known as Aspergillus section Nigri [10].
- Cryptic Species: There are several closely related species within this group (such as A. tubingensis and A. welwitschiae) that look identical to A. niger under a standard microscope [10][11]. These are called cryptic species because they cannot be distinguished by appearance alone [11].
- Testing Limitations: Some routine lab methods cannot reliably tell these cryptic species apart. As a result, labs may simply report any dark Aspergillus mold as an “A. niger group” result [10][12]. When researchers use advanced DNA testing, they often find that some isolates labeled as A. niger were actually caused by these closely related cryptic species [10][12].
Because exact identification requires advanced testing (like molecular sequencing or MALDI-TOF), the exact species name is not always confirmed unless it would change your treatment plan [10][11].
Does the Frequency of the Fungus Predict Severity?
Patients often wonder if having a less common species of Aspergillus changes their prognosis. The exact species name alone cannot predict your outcome [5].
While comparative studies do not show a consistent difference in survival based solely on whether a patient has A. niger or A. fumigatus [5][13], the specific species can affect expected resistance mechanisms and which antifungal medications might work best.
Rather than focusing just on how common the fungus is, your medical team will look at the whole picture to determine your prognosis and treatment plan:
- Your Immune System: Your underlying health, whether you have conditions like diabetes or chronic lung disease, and whether you are taking immunosuppressive medications are strong predictors of how your body will handle the infection [13].
- Location and Spread: Whether the infection is localized (like in the outer ear) or invasive (spreading through tissue or other organs) makes a massive difference in severity and urgency [5].
- Antifungal Susceptibility: Whether the specific fungal isolate you have is susceptible (can be killed by) or resistant to standard antifungal medications is critical. Both the exact organism identification and susceptibility testing are considered together when choosing a treatment [14].
When to Seek Urgent Medical Attention
Being diagnosed with a mold infection can be frightening, but your care team determines the significance of the infection from your whole clinical picture, not just the name of the fungus. Do not start, stop, or change antifungal treatment based on the species name alone. Depending on where your infection is, certain symptoms warrant urgent medical review:
- For lung or invasive infections: Seek immediate emergency care for new or worsening shortness of breath, chest pain, coughing up blood, persistent fever, confusion, or a rapid decline in your health.
- For ear infections: Contact your clinician promptly if you experience worsening severe pain, fever, redness and swelling spreading beyond the ear, severe dizziness, or sudden changes in your hearing.
Common questions in this guide
Which is usually more common, Aspergillus niger or Aspergillus fumigatus?
Does Aspergillus niger in a sputum sample always mean I have an infection?
Why might my report say Aspergillus niger group instead of an exact species?
Does Aspergillus niger usually cause a milder illness than Aspergillus fumigatus?
Can the Aspergillus species change which antifungal medicine I need?
What symptoms need urgent medical attention with an Aspergillus infection?
Related questions
Show more
Get notified when new evidence is published on Aspergillus niger infection.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
Distribution of Aspergillus species and risk factors for aspergillosis in mainland China: a systematic review.
Khan S, Bilal H, Shafiq M, et al.
Therapeutic advances in infectious disease 2024; (11()):20499361241252537 doi:10.1177/20499361241252537.
PMID: 38835831 - 2
A prospective survey of Aspergillus spp. in respiratory tract samples: Species identification and susceptibility patterns.
Castro C, Galán-Sanchez F, Linares MJ, et al.
Medical mycology 2019; (57(4)):412-420 doi:10.1093/mmy/myy080.
PMID: 30289467 - 3
Species distribution and antifungal susceptibility of clinical Aspergillus isolates: A multicentre study in Taiwan, 2016-2020.
Wang HC, Hsieh MI, Choi PC, et al.
Mycoses 2023; (66(8)):711-722 doi:10.1111/myc.13593.
PMID: 37186489 - 4
Otomycosis: a systematic review and meta-analysis of prevalence and causative agents in the era of molecular diagnostics.
Nazari T, Peymaeei F, Ghazi Mirsaid R, et al.
BMC infectious diseases 2025; (25(1)):544 doi:10.1186/s12879-025-10954-y.
PMID: 40247196 - 5
Characteristics of culture-positive invasive pulmonary aspergillosis in patients with hematologic diseases: Comparison between Aspergillus fumigatus and non-fumigatus Aspergillus species.
Cho SY, Lee DG, Choi JK, et al.
Medicine 2017; (96(49)):e8841 doi:10.1097/MD.0000000000008841.
PMID: 29245249 - 6
Chronic pulmonary aspergillosis in a tertiary care centre in Spain: A retrospective, observational study.
Aguilar-Company J, Martín MT, Goterris-Bonet L, et al.
Mycoses 2019; (62(9)):765-772 doi:10.1111/myc.12950.
PMID: 31162731 - 7
Clinical characteristics and prognosis of COVID-19- associated invasive pulmonary aspergillosis in critically patients: a single-center study.
Xiao S, Xu J, Xiao H, et al.
Frontiers in cellular and infection microbiology 2025; (15()):1522217 doi:10.3389/fcimb.2025.1522217.
PMID: 40330022 - 8
Clinical characteristics of patients with Aspergillus species isolation from respiratory samples: Comparison of chronic pulmonary aspergillosis and colonization.
Ohara S, Tazawa Y, Tanai C, et al.
Respiratory investigation 2016; (54(2)):92-7.
PMID: 26879478 - 9
Non-fumigatus Aspergillus-associated pulmonary events: a diagnostic challenge.
Godet C, Joste V, Frat J-P, et al.
Journal of clinical microbiology 2026; (64(4)):e0016326 doi:10.1128/jcm.00163-26.
PMID: 41848336 - 10
Species Distribution and Comparison between EUCAST and Gradient Concentration Strips Methods for Antifungal Susceptibility Testing of 112 Aspergillus Section Nigri Isolates.
Carrara B, Richards R, Imbert S, et al.
Antimicrobial agents and chemotherapy 2020; (64(7)) doi:10.1128/AAC.02510-19.
PMID: 32312779 - 11
The accuracy and clinical impact of the morphological identification of Aspergillus species in the age of cryptic species: A single-centre study.
Takeda K, Suzuki J, Watanabe A, et al.
Mycoses 2022; (65(2)):164-170 doi:10.1111/myc.13397.
PMID: 34783396 - 12
Clinical and microbial epidemiology of otomycosis in the city of Yasuj, southwest Iran, revealing Aspergillus tubingensis as the dominant causative agent.
Sabz G, Gharaghani M, Mirhendi H, et al.
Journal of medical microbiology 2019; (68(4)):585-590 doi:10.1099/jmm.0.000948.
PMID: 30801244 - 13
Non-Aspergillus fumigatus mould infections in lung transplant recipients: an international, multicentre, case-control study.
Henry B, Walti LN, Kothari S, et al.
The Lancet. Microbe 2026; (7(9)):101352 doi:10.1016/j.lanmic.2026.101352.
PMID: 42419340 - 14
Epidemiology and Antifungal Susceptibility Profile of Aspergillus Species: Comparison between Environmental and Clinical Isolates from Patients with Hematologic Malignancies.
Cho SY, Lee DG, Kim WB, et al.
Journal of clinical microbiology 2019; (57(7)) doi:10.1128/JCM.02023-18.
PMID: 31018982
This page is for informational purposes only and does not constitute medical advice. Your clinician should interpret the culture, symptoms, imaging, and susceptibility results before deciding whether treatment is needed.